Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aronex Pharma (ARNX) -- Ignore unavailable to you. Want to Upgrade?

To: Dexter Enders who wrote (56)	12/11/1997 9:05:00 PM
From: Robert Floyd	Read Replies (1) \| Respond to of 320

Probably the phrase: " In part as a result of this expanded program and in part as a result of a recent informal meeting with the Food and Drug Administration, Aronex Pharmaceuticals has decided to delay the filing of a New Drug Application for ATRAGEN to enable enrollment of additional patients with APL and other cancers. The Company believes these expanded clinical trials will effectively support the long-term commercialization of the product." A delay in the filing may not be considered good news by some. This company currently has no income producing products, and is relying on the hope of success in the future. Their initial announcement of the plans to file may have raised expectations that some fruit was soon to be forthcoming.